Bibliographic Details
| Title: |
Dual enhancement in the radiosensitivity of prostate cancer through nanoparticles and chemotherapeutics. |
| Authors: |
Jackson, Nolan, Hill, Iona, Alhussan, Abdulaziz, Bromma, Kyle, Morgan, Jessica, Abousaida, Belal, Zahra, Yasmin, Mackeyev, Yuri, Beckham, Wayne, Herchko, Steven, Krishnan, Sunil, Chithrani, Devika Basnagge |
| Source: |
Cancer Nanotechnology (1868-6958); 9/29/2023, Vol. 14 Issue 1, p1-22, 22p |
| Subject Terms: |
RADIATION tolerance, CELL culture, DOUBLE-strand DNA breaks, PROSTATE cancer, GOLD nanoparticles, RADIATION damage |
| Abstract: |
Background: Radiotherapy (RT) is an essential component in the treatment regimens for many cancer patients. However, the dose escalation required to improve curative results is hindered due to the normal tissue toxicity that is induced. The introduction of radiosensitizers to RT treatment is an avenue that is currently being explored to overcome this issue. By introducing radiosensitizers into tumor sites, it is possible to preferentially enhance the local dose deposited. Gold nanoparticles (GNPs) are a potential candidate that have shown great promise in increasing the radiosensitivity of cancer cells through an enhancement in DNA damage. Furthermore, docetaxel (DTX) is a chemotherapeutic agent that arrests cells in the G2/M phase of the cell cycle, the phase most sensitive to radiation damage. We hypothesized that by incorporating DTX to GNP-enhanced radiotherapy treatment, we could further improve the radiosensitization experienced by cancer cells. To assess this strategy, we analyzed the radiotherapeutic effects on monolayer cell cultures in vitro, as well as on a mice prostate xenograft model in vivo while using clinically feasible concentrations for both GNPs and DTX. Results: The introduction of DTX to GNP-enhanced radiotherapy further increased the radiotherapeutic effects experienced by cancer cells. A 38% increase in DNA double-strand breaks was observed with the combination of GNP/DTX vs GNP alone after a dose of 2 Gy was administered. In vivo results displayed significant reduction in tumor growth over a 30-day observation period with the treatment of GNP/DTX/RT when compared to GNP/RT after a single 5 Gy dose was given to mice. The treatment strategy also resulted in 100% mice survival, which was not observed for other treatment conditions. Conclusions: Incorporating DTX to work in unison with GNPs and RT can increase the efficacy of RT treatment. Our study suggests that the treatment strategy could improve tumor control through local dose enhancement. As the concentrations used in this study are clinically feasible, there is potential for this strategy to be translated into clinical settings. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Nanotechnology (1868-6958) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
